David Feldker has been appointed chief executive officer and president of Reliable Biopharmaceutical Corp. (RBC). Mike Zaleski will be stepping down as RBC’s president and chief executive officer, effective October 22, 2010 but will remain an advisor to the board of directors during the transition. Mr. Feldker was previously vice president SAFC at Sigma-Aldrich Corp., responsible for the API contract development and manufacturing segment.

“David built SAFC Pharma into one of the leading developers and manufacturers of High Potency APIs and Biologic Ingredients” said RBC chairman James A. Breckenridge. “As RBC continues to grow, David is the perfect executive to lead RBC and capitalize on its complex chemistry capabilities, strong customer relationships as well as its robust API pipeline for generic injectable drugs.”

“RBC has built an excellent reputation around high purity ingredients and active pharmaceutical ingredients,” said Mr. Feldker. “The company has accomplished a great deal over the past few years and I look forward to working together to take it to the next level.”